Recognised for its key role in lactation, it is less well appreciated that the neurohormone prolactin (PRL) is actually one of the most pleiotropic hormones known. Not only does PRL exert both tropic and trophic effects in a wide range of tissues, but it is also expressed in human skin and hair follicles and regulates multiple complex cutaneous functions, including keratin expression and hair growth. Despite several clinical indications that PRL may also play a role in sebaceous gland (SG) biology, the effects of PRL on SG function have received little attention. In this Viewpoint essay, we argue that PRL may be a sebotrop(h)ic hormone and could represent a novel therapeutic target in human dermatoses affecting the SG. We provide preliminary evidence in support of this hypothesis (based on findings in human skin organ culture) and chart the major open questions in SG biology and pathology from a PRL research perspective. We close by delineating how these questions can be experimentally addressed so as to identify new therapeutic strategies that are either sebogenic or sebostatic, for example in the management of acne and cutaneous ageing.
| INTRODUC TI ON
The human pilosebaceous unit (PSU), comprising most prominently the hair follicle (HF) and the sebaceous gland (SG), which inserts into HF's distal outer root sheath and uses the hair shaft to distribute sebum on the epidermal surface, is one of the major skin appendages and is almost ubiquitously present throughout the entire integument, with notable exceptions such as the palms, soles and labial skin. Clinically, acne vulgaris, the most common, multi-factorial, hormone-dependent skin disease in humans, [1, 2] is the most frequent pathological condition associated with the PSU. [3] Given that the disease can persist well into adulthood, the associated healthcare costs, but more importantly the impact upon quality of life, are significant. [4] Human PSU research has somewhat focussed on the HF and tends to relatively neglect the SG, not to mention the eccrine glands which may well be an integral component of the PSU. [5] This likely reflects the relative ease with which scalp HF can be microdissected and cultured in serum free medium ex vivo. [6, 7] In contrast, the practical and technical difficulties associated with the ex vivo culture of SGs, [8] [9] [10] not to mention the scarcity of generally accepted, standardised functional read-out parameters for assessing human SG function in situ in preclinical assays, have somewhat hampered the development of ex vivo tissue-level human SG research. [9, 11] The recent development of a standardised approach to the study of human SGs in situ [12] has facilitated re-examination of the hormonal regulation of SG function in short-term full-thickness human skin organ culture. [13] The SG is not only an important endocrine target organ, which is likely important in the context of the sex-steroid-dependence of acne vulgaris, [14, 15] but also a prominent source of a diverse repertoire of hormones, some of which, including androgens and oestrogens may be metabolised within the SG. [9, [16] [17] [18] [19] [20] Nevertheless, comparatively little is known about the direct effects of hormones on human SG function in situ. There is a wealth of published data reporting how various hormones and other mediators impact on isolated, cultured human sebocytes, typically using immortalised sebocyte cell lines. [21] [22] [23] [24] Given the importance of cell death signalling in acne treatments, the use of immortalised sebocyte cell lines to study acne pathogenesis has recently been challenged. [25, 26] Thus, while experimental data from sebocyte cell lines provide important pointers, they cannot substitute appropriate in situ analyses, where primary, unmanipulated human sebocytes are analysed within their natural tissue habitat.
More recent efforts have focussed on developing co-culture models, for example with SZ95 sebocytes and ex vivo skin explants, to examine the interaction between the SG and other skin compartments, revealing the importance of the SG in the maintenance of cutaneous homoeostasis [27, 28] and three-dimensional culture of SGs. [29, 30] The advantage of in situ studies is the maintenance of the physiological epithelial-mesenchymal interactions between SG epithelium and stroma, including relevant signalling events related to the extracellular matrix, even if SG innervation and vascularisation cannot be maintained ex vivo.
On this background, the current viewpoint essay examines pointers from the literature as well as from limited, available preliminary data that one specific neurohormone may operate as a translationally important SG regulator: the pleiotropic peptide hormone, prolactin (PRL), which is primarily synthesised and secreted by the anterior pituitary gland. [31, 32] We examine the evidence that PRL is an elusive, long-forgotten sebotrop(h)ic factor, which can both target the SG (sebotropic) and stimulate sebocyte proliferation (sebotrophic) and present preliminary research data, building on novel methodological approaches to the study of human SGs in situ, which support this concept. We then illustrate how the role of PRL and other (neuro-)endocrine candidate agents as direct regulators of human SG physiology can be experimentally dissected under preclinical conditions in situ, in the absence of confounding systemic or neural inputs. The essay closes by exploring how insights won from this approach could help to identify new acne treatment strategies. In fact, it was first speculated over four decades ago that "a pituitary factor" may regulate sebum production, [33] but has since never been systematically explored. This
Viewpoint essay takes the opportunity to redress the balance.
| PROL AC TIN AND THE SG
Prolactin is secreted under dopaminergic inhibitory control by the anterior pituitary gland, [34] and may modulate SG function, as part of the "brain-skin axis". [35] [36] [37] This has long been suggested by the seborrhoea initially reported with clinical hyperprolactinaemia [38] and the association of seborrhoea/seborrhoeic dermatitis with
Parkinson's disease, [39, 40] which may reflect the increased peak nocturnal PRL levels reported in patients with Parkinson's disease. [41] For an in-depth discussion of the relationship between PRL and
Parkinson's disease, see the Supplementary text (S1).
However, surprisingly few inroads have been made into the PRL-SG connection. The discoveries that human skin and HFs are extrapituitary sources of PRL [42] [43] [44] and that PRL potently modulates key aspects of human skin and HF biology [42, [45] [46] [47] and the development of short-term serum free skin organ culture which can be complemented by in situ immunomorphometry, [48, 49] encourages reexamination of PRL as a sebotrop(h)ic hormone.
| HIS TORIC AL PER S PEC TIVE
Almost a century ago, Cohn described seborrhoea as a symptom of postencephalitic Parkinson's disease. [50] Much later, these findings were replicated in patients with both postencephalitic and idiopathic
Parkinson's disease, [51] characterised by a loss of dopaminergic neurons in the substania nigra. [52] Interestingly, although sebum production was increased in patients with various neurological diseases, the association with seborrhoea was only statistically significant in patients with Parkinson's disease: both postencephalitic and idiopathic. [51] Subsequent studies, albeit small, confirmed increased sebum production in Parkinson's disease, and, importantly, demonstrated reduced seborrhoea in response to treatment with L-Dopa. [53] Whilst one study did not demonstrate any effect of L-Dopa on either rate of excretion or composition of sebum in patients with Parkinson's disease, [54] Burton et al [33] reported that L-Dopa treatment resulted in a significant reduction in the rate of sebum excretion in those patients with raised baseline levels of sebum excretion and postulated that any "sebotrophic hormone is under inhibitory control." [33] 
| E SS ENTIAL S OF SG B I OLOGY
The human SG is a crucially important epidermal derivative, intimately linked with the HF and the arrector pili muscle, and arguably perhaps even the eccrine gland [5] to form the PSU. [12] Provocatively, the SG has even been postulated to represent the "brain of the skin". [55] Physiologically, SGs are comprised of lipid-containing sebocytes which develop form the peripheral germinative layer, and terminally differentiate to produce sebum by holocrine secretion, which is extruded via the sebaceous duct into the infundibulum of the HF ( Figure 1 ). [20] F I G U R E 1 The human SG. Considered as a mini-organ in its own right, the human SG consists of a single cell type, the sebocyte. Present on all skin surfaces excluding the palms and soles, the SGs are responsible for the production of sebum. Sebum production is via holocrine secretion from sebocytes, meaning that differentiation and apoptosis are required for the release of sebum. The sebum is secreted via the sebaceous duct into the HF at the level of the infundibulum. Scale bar represents 200 μm, and the histology is from a periodic acid-Schiff stain Indeed, the SG itself is now known to be an astonishingly rich source, and target, of multiple hormones and adipokines, [56, 57] recently classified by Chen et al [15] into amino acid/oligo-/polypeptide, glycoprotein, lipid/steroid, phospholipid and retinoid hormones. Even within the SG itself, compartment-specific expression of hormones and/or their cognate receptors may exist. For example, the androgen receptor appears to be restricted to basal layer sebocytes. [58] Moreover, although the SG and HF are intimately related, there is also variable/compartment-specific expression of both hormone receptors and the key enzymes in steroid hormone biosynthesis within the PSU. [59] [60] [61] [62] In addition, the SG intensively engages in hormone metabolism, not only (but particularly prominently) in steroid hormone metabolism, [15, 63, 64] but also metabolises, for example important, multi-functional lipid mediators that form part of the skin's endocannabinoid, [13, 65, 66] endovanilloid [67, 68] or eicosanoid systems.
[69]
| PROL AC TIN E XPRE SS I ON IN THE S K IN
Prolactin gene expression has been reported using conventional reverse transcriptase polymerase chain reaction technology (RT-PCR)
in both freshly dissected human scalp skin and isolated, organ-cultured human scalp HFs. [42] Moreover, PRL mRNA expression has been shown in human dermal fibroblasts using Northern blot. As expected, the mRNA product was 150 bp longer than the pituitary PRL mRNA owing to the extrapituitary alternative promoter. [70] More recently, both PRL and PRLR expression has been demonstrated in outer root sheath keratinocytes, organ-cultured female HFs and corporal skin, at the gene and/or protein level, and key regulators of PRL expression have been identified [43, 71] ( Figure S1 ). Moreover, that intracutaneous PRL gene and protein expression further increased in organ-cultured human skin [43] demonstrated the capacity of human skin to engage in PRL synthesis. That Slominski et al [72] failed to identify PRL gene expression in a range of healthy and pathological human skin specimens may have been related to the primers used and the specific skin locations investigated.
Indeed, the expression of PRL in human skin is only now gaining more widespread acceptance in endocrinology. [31, 44, 47, [73] [74] [75] [76] [77] [78] Furthermore, human keratinocytes, human skin and human HFs are known to express the PRLR protein, [42, 71, 79] and PRLR signalling is functional in human skin, as evidenced by STAT5 activation which is typically activated by the long PRLR isoform.
[43]
| E VIDEN CE THAT PRL IMPAC TS UP ON SG B I OLOGY
PRLR expression, at the protein level, has been reported in the human SG [42] and at the gene level in human outer root sheath keratinocytes. [43] The HF, the other key component of the PSU, has been shown to express both PRL at both the gene and the protein levels, [42, 43] supporting local PRL production. Given that increased sebum production (lipid synthesis) is dependent upon increased sebocyte proliferation [21] (Figure S2 ), PRL may directly stimulate sebocyte proliferation in an auto/paracrine manner. Alternatively, it has been proposed that PRL may indirectly influence SG function via modulation of androgen metabolism. [16, 80, 81] However, hyperprolactinaemia is often associated with decreased serum testosterone concentrations in males [62] and PRL has also been shown to decrease 5-alpha reductase activity, at least in vitro in female genital skin from normoprolactinaemic non-hirsute women. [80] Given that androgens are often thought to play an "obligatory role" [19] in acne development, the mechanism(s) through which hyperprolactinaemia results in the clinical manifestation of acne, therefore, are not immediately apparent.
Perhaps, besides a direct signalling effect on PRLR-expressing sebocytes, one additional answer lies in the complex interactions between central and peripheral androgen metabolism and PRL.
Moreover, the sexual dimorphism in serum PRL concentrations must also be borne in mind (non-pregnant females 10-25 ng/mL, males 5-10 ng/mL [82] ). Moreover, since it is known that female frontotemporal human scalp HFs show very different responses to PRL stimulation ex vivo compared to male occipital HFs, [45] this sex-and/or location-dependent difference in the reponse of the HF to PRL may also extend to other components of the PSU.
Clinically, hyperprolactinaemia is principally associated with acne development in females, [40, 83] whilst decreased shaving frequency and body hair are the most common skin manifestations of hyperprolactinemia in males. [16, 62, 81] Therefore, hyperprolactinaemia may not be associated with acne development per se, but rather may reflect increased adrenal androgen production, as it is recognised to occur in the context of increased circulating PRL levels. [84] In females, this may be sufficient to promote acne development. Instead, in males, the hypoandrogenism associated with hyperprolactinaemia may not be conducive to acne development. In any case, the specific contribution of skin-derived androgens to the development of acne, especially in the context of hyperprolactinaemia, remains unknown.
| HYP OTHE S IS
Based on the literature cited above and clinical observations, we hypothesize that PRL is capable of modulating human SG function both directly and indirectly. If confirmed, the modulation of intracutaneous PRL activity, using topically applied PRLR antagonists, may represent a novel therapeutic strategy to regulate SG function, for example in the management of acne, possibly without impacting upon circulating PRL and androgens levels.
| TE S TING THE HYP OTHE S IS
To experimentally confirm or refute the role of PRL as a modulator of human SG gland function, short-term serum free ex vivo organ culture of SG-bearing human skin can be performed, using established skin organ culture methodology. [13, 43, 48, 49] Not only does this allow examination of the direct effect of exogenous PRL in the absence of systemic in human skin (e.g. endocrine, vascular and nutritional) and neural signalling, but it also permits one to selectively interfere with PRL signalling in human skin (e.g. by administering PRLR antagonists, [73] or by attempting to knock-down intracutaneous PRLR or PRL expression, using simple siRNA transfection methods that have recently been successfully employed for the silencing of other genes in human skin or HF organ culture. [85] [86] [87] 
| THE NEED FOR ORG AN CULTURE MODEL S IN H UMAN SG RE S E ARCH
A thorough dissection of the role of PRL in human SG physiology has been hampered by the lack of an appropriate, serumfree skin culture model, technical difficulties in the analysis of SG function ex vivo and a reliance on rodent models that are ill-suited to study extrapituitary PRL functions and regulation in human skin (Table S1 ). In order to highlight the importance of using human organ culture models in extrapituitary PRL research and to underscore the signalling levels at which PRL may impact on the SG, a brief précis of PRL biology is outlined in the supplement (Data S1).
| PRELIMINARY E VIDEN CE IN SUPP ORT OF THE HYP OTHE S IS
As a first step towards probing the above hypothesis, we have recently utilised serum-free full-thickness human skin organ culture, [49] thus excluding confounding, vascular, systemic endocrine, nutritional or neural regulatory inputs on SG function, have employed a specific PRLR antagonist (∆1-9-G129R-hPRL), in the presence of PRL (400 ng/ml) to test the effects of PRL on human SG function ex vivo ( Figure S3 ). The PRLR antagonist was selected given its ability to reverse the effect of PRL in the pilosebaceous unit, at least in terms of keratin expression, control of epithelial progenitor cell functions [46] and hair shaft elongation. [45] All patients provided written informed consent according to the Helsinki principles, and ethical approval was obtained from the University of Luebeck ethics committee.
These pilot assays showed by quantitative histomorphometry that PRL indeed increased the SG area (and thus likely the SG volume) in human skin ex vivo and significantly increased the percentage of proliferating basal layer sebocytes in situ, based on the ratio between basal and mature sebocytes ( Figure S4 ). In order to determine whether the increased SG area actually corresponded to increased lipid production, oil red and sudan black histochemistry was performed. This showed that PRL treatment increased lipid production in the SG in a PRLR-dependent manner ( Figure S5 ), the addition of PRLR antagonist (tenfold molar excess of antagonist was used to block exogenous PRL [88] ) prevented increased lipid production. It should be borne in mind that the mean intensity was measured per area, therefore, the increased staining intensity does not simply reflect increased gland size, but likely reflects a true increase in actual lipid production. Additional preliminary experiments suggested that PRL also up-regulates 5-alpha-reductase type 1 protein expression in the human SG ex vivo ( Figure S6 ).
Obviously, this very preliminary evidence from a first pilot study performed with organ-cultured normal human skin derived from three different females remains to be repeated and extended before PRL can be fully accepted as major sebotrop(h)ic factor.
However, these limited data already lend credence to the concept as such.
| CON CLUS IONS AND TR ANS L ATIONAL PER S PEC TIVE S
Combining skin and HF organ culture models, ideally using tissue from the same subjects, may represent an effective strategy to tease out which effects of PRL are SG dependent. Indeed, specific culture of skin and HFs from patients with Parkinson's disease may also shed new light on the extent to which the clinically observed seborrhoea is dependent on the hypodopaminergic state per se, or a resultant increased PRL secretion. Given that dopamine itself actually is a direct inhibitor of human scalp HF growth ex vivo [43] one wonders whether it also negatively regulates sebocyte proliferation and sebum production, thus possibly explaining the association of a Thus, decades after the first clinical reports from patients with Parkinson's disease had raised the possibility that PRL may stimulate human SG function [39] and indications that PRL modulates peripheral androgen metabolism, [80] Figure 2 ).
If this hypothesis is independently confirmed, PRL will have to be counted among the growing ranks of sebotrop(h)ic factors that regulate sebum production, such as androgens [89] and endocannabinoids. [13, 65] Likely, the overall impact and net result of these (neuro-)endocrine regulators on human SG physiology and pathology will depend on the simultaneous local presence and activity level of modulators of SG function and sebum production, for example retinoids, [90] PPAR gamma signalling, [69, 91, 92] aryl hydrocarbon receptor ligands, [93] interleukin 6 [22] and oestrogen. [94] Whilst non-selectively modulating circulating PRL levels to regulate SG function is clearly undesirable, substances which modulate PRL/PRLR expression in human skin (at least ex vivo) [43] could be investigated for their effects on SG biology and pathology. The major translational research challenge remains to selectively target skin site-specific human SG function in a therapeutically desired manner by topically applied agents (eg reducing sebum production in acne, whilst stimulating it in sebostatic dermatoses) as we deepen our understanding of the "brain-skin axis". [36, 47, 74, 95] 
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TA B L E 1 Major open-ended questions
Future Research Directions
Are PRL's sex-/location dependent effects on human HFs partially mediated by the SG in general, and by PRL-mediated modulation of peripheral androgen metabolism in particular?" If so, are the sex-dependent effects of PRL on the HF partly due to increased production of dihydrotestosterone via increased 5AR1 activity, thus contributing to the well described effects of dihydrotestosterone on the HF, namely miniaturisation of terminal HFs and transformation of vellus to terminal HFs dependent on skin location [96] (Fig. 2) ?".
Confirmation is needed that PRL indeed increases human sebocyte proliferation in situ (Fig. S7) , since this would. Moreover, extended co-culture studies of PRL together with selective PRLR antagonists are required, not only to provide further evidence that PRL is acting via its receptor, but also to further probe which PRLs effects are direct, and which one are mediated by changes in the expression of other hormone receptors.
It should be borne in mind that many of the reported effects of PRL on HF biology have been obtained using microdissected HFs, that is in the absence of the SG. [42, 45, 46] Future studies comparing the effects of PRL on microdissected HFs, and those present in full-thickness skin from the same individual, may help to determine whether differences in the response of the HF to PRL are SG dependent. Availability of an adequate amount of tissue would be the main challenge in planning these studies.
Another challenge in determining whether PRL can induce HF miniaturisation via increased SG androgen production is the fact that such effects would be dependent upon repeated HF cycling, which is currently not possible using the human HF organ culture model. However, if the full-thickness skin model can be modified to support full HF cycling, observing the effect of PRL on the HF during repeated cycles would help determine whether PRL acts as an androgen mimic. In any case, it should also be recognised that PRL also influences HF biology in the absence of the SG, for example in HF organ culture. [42, 45, 46] The importance of the cutaneous microbiome in skin disease [97] [98] [99] [100] in general and in acne vulgaris in particular [101] [102] [103] [104] is increasingly being recognized. Finally, therefore, the potential neuroendocrine regulation of the cutaneous microbiome, representing a surface area of approximately 25 m 2 when the inner follicular epithelium is included [105] , potentially via PRL generated within the HF epithelium
itself, may open up a new research frontier in human PSU biology.
F I G U R E 2 Effects of PRL on the SG. Using full-thickness skin organ culture, PRL was shown to potently regulate key parameters of SG biology (1) (2) (3) (4) . This leads to the hypothesis that PRL may exert androgen-like effects on the HF via increased androgen metabolism. Illustration modified from Ref.
[47]
The effects of PRL on the sebaceous gland ex vivo with PRL treatment (C). Results were pooled from 3 female subjects (aged . For gland area, data for treatment group and subject were log(10) transformed and 2-way ANOVA, controlling for subject effect (P = .005). Student's t tests were used to determine differences between control and PRL groups in terms of percentage of sebocytes FIGURE S5 PRL stimulates total lipid production. Consistent with the observations seen in terms of the effect of PRL on the production of neutral lipids, triglycerides and cholesterol esters in situ, PRL stimulated overall lipid production in the SGs. This effect was also reversed by the addition of PRL plus PRLR antagonist. Scale bars represent 50 μm FIGURE S6 PRL increases 5AR1 IR in the human SG. PRL increased 5AR1 IR, but the effect was not statistically significant (p = 0.054).
Results pooled from 3 female subjects. Scale bars represent 50 μm 
FIGURE S7
